Laurion Capital Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

Laurion Capital Management’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-13,392	Closed	-$283K	–	994
2019 Q2	$283K	Sell	13,392 -5,682	-30%	-$119K	﹤0.01%	782
2019 Q1	$390K	Buy	+19,074	New	+$427K	0.01%	668
2018 Q1	–	Sell	-17,100	Closed	-$329K	–	1307
2017 Q4	$329K	Buy	+17,100	New	+$319K	﹤0.01%	1300

Other funds holding AMPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Laurion Capital Management's AMPH Position: Q3 2019 in Review

Laurion Capital Management sold out of Amphastar Pharmaceuticals (AMPH) in Q3 2019, closing a stake of 13,392 shares — an estimated $283K sold.

Laurion Capital Management first reported a position in AMPH in Q4 2017 and held it in 3 quarters. The position peaked at $390K in Q1 2019. 134 funds tracked by Wall St. Rank hold AMPH as of Q3 2019.

Laurion Capital Management reported no remaining Amphastar Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Laurion Capital Management sold 13,392 Amphastar Pharmaceuticals shares in Q3 2019, an estimated $283K.
Laurion Capital Management first reported a position in Amphastar Pharmaceuticals in Q4 2017 and held it in 3 quarters.
Laurion Capital Management's Amphastar Pharmaceuticals position peaked at $390K in Q1 2019.
134 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q3 2019.

Based on Laurion Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.